The switch from fetal to adult hemoglobin

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• The switch from fetal hemoglobin (HbF) to adult hemoglobin is a critical developmental process.
• Clinical induction of HbF is a promising therapeutic avenue for hemoglobinopathies like sickle cell disease (SCD) and beta-thalassemia.
• Understanding the regulation of HbF silencing is key to developing effective treatments.

Purpose of the Study:

• To review historical and recent strategies for inducing fetal hemoglobin (HbF) production.
• To highlight the role of molecular regulators such as BCL11A, MYB, and KLF1 in HbF induction.
• To discuss the development of targeted approaches for HbF induction.

Main Methods:

• Chronological review of research spanning four decades in HbF induction.
• Discussion of molecular studies identifying key regulators of HbF silencing.
• Analysis of therapeutic strategies for managing SCD and beta-thalassemia through HbF induction.

Main Results:

• Historical attempts at HbF induction have led to some therapeutic approaches for SCD and beta-thalassemia.
• Molecular studies have identified crucial regulators (BCL11A, MYB, KLF1) for targeted HbF induction.
• These regulators offer potential for developing more effective and precise therapeutic strategies.

Conclusions:

• Targeted induction of HbF, guided by identified molecular regulators, holds significant promise for treating SCD and beta-thalassemia.
• Lessons from past research are vital for advancing future HbF induction strategies.
• Continued research into HbF regulation can lead to improved clinical outcomes for patients with hemoglobinopathies.